Guest Column | June 10, 2026 By Johnathon Anderson, Ph.D. The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding. We saw the technological architecture laid out at the American Society of Gene and Cell Therapy (ASGCT) meeting. Weeks later, the American Society of Clinical Oncology (ASCO) provided the hard clinical evidence that these platforms actually work in human patients.
Johnathon Anderson
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Johnathon
Contact Johnathon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack